What the NHS guidelines say about Mounjaro — and what they mean for you

What NICE TA1026 actually requires — and why the cohort system exists

NICE published its recommendation for tirzepatide in December 2024, updated in September 2025. Rather than opening access to all eligible adults at once, NHS England designed a staged rollout to manage demand while specialist services scale up. The prescribing guidelines for Mounjaro on the NHS are therefore best understood as a queue, not a door.

The first cohort, active from June 2025, covers adults with a BMI of 40 or above who also have four or more of five defined weight-related conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. The second cohort opened in June 2026, extending access to people with a BMI between 35 and 39.9 who also carry four or more of those same conditions. A third cohort, expected around March 2027, will move the threshold down to three qualifying conditions for people with a BMI of 40 or above. For some ethnic backgrounds (including South Asian, Chinese, Middle Eastern, Black African, and African-Caribbean) the BMI figures are each reduced by 2.5 kg/m², reflecting evidence that metabolic risk accumulates at lower weights in those populations. How BMI thresholds work in practice under the NHS criteria is worth reading if you are close to a borderline.

One thing worth gently setting aside: a common assumption is that meeting the NICE BMI and condition criteria guarantees a prescription. It does not. Every patient still needs full clinical assessment, wrap-around dietary and activity support, and a prescription from a qualified healthcare professional. Meeting the numbers is the starting point, not the finish line.

What the NHS guidelines say about how long treatment continues

NICE TA1026 includes a review clause that clinicians must apply: if a patient has not lost at least 5% of their body weight after six months on the highest dose they can tolerate, the guideline recommends reconsidering whether treatment should continue. This is consistent with how the guideline approaches proportionate use of NHS resources and mirrors the clinical logic behind titrated treatment generally.

The treatment itself begins at 2.5 mg, a dose chosen to help your system adjust rather than for its therapeutic weight-loss effect, and is stepped up by the prescriber over several months toward higher maintenance doses. What NHS access to Mounjaro looks like in practice covers the service pathway in more detail, including the wrap-around support requirement that every NHS patient must receive alongside the medicine.

From 1 April 2026, some GP practices can prescribe tirzepatide directly under the new GP contract as part of QOF 2026/27. Participation is voluntary, so provision varies significantly by area. If your practice is not yet offering this, a referral to a specialist weight management service remains the standard NHS route, and waiting lists in those services are often long. NICE's full recommendations for tirzepatide (TA1026) are publicly available if you want to read the exact wording.

Private prescribing criteria compared with the NHS guidelines

The licensed criteria in the Mounjaro SmPC are broader than what NICE prescribes for NHS use. Privately, a prescriber can consider tirzepatide for adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, conditions such as prediabetes, hypertension, high cholesterol, or obstructive sleep apnoea. There is no requirement to have four co-morbidities, and no phased cohort to pass through. The medicine is the same; the access pathway is different.

For many people the NHS cohort criteria simply do not apply to their situation yet, or the wait for a specialist service is measured in months. Private treatment through a regulated online pharmacy is a legal, clinically supervised alternative. You can read about how to access Mounjaro through a private online pharmacy and what the process involves, or explore how private Mounjaro pricing works if cost is a consideration. The full Mounjaro treatment overview on our site covers the clinical picture from first dose to ongoing review.

One practical note: a prescriber will always assess your whole health picture, not just your BMI. Contraindications, other medicines, and individual history all shape the decision. NHS England's guidance on weight management injections covers the clinical framework in detail, including the contraception and surgery considerations that apply to anyone on tirzepatide, regardless of NHS or private route.

What to do if you think you might qualify, NHS or private

If you believe you meet the current NHS cohort criteria, the starting point is your GP. Ask specifically whether your practice participates in the 2026/27 GP contract scheme, or whether a referral to a specialist weight management service is appropriate. Be prepared for a wait in either case. Demand across England significantly outpaces current NHS capacity.

If you are not within the current NHS cohort, or you would rather not wait, a private clinical assessment is the alternative. At nume, a GPhC-registered Independent Prescriber reads every consultation personally on the same day it is submitted. There is no algorithm involved, no subscription, and no hidden fees: consultation, prescription, treatment, and tracked next-working-day delivery are covered in one transparent price. You can verify our pharmacy on the GPhC register, our premises registration is 9012878.

Our frequently asked questions answer many of the practical queries around eligibility and the consultation process, and if you want to speak to someone directly our contact page will reach the aftercare team. When you are ready, start your free consultation and a prescriber will assess whether Mounjaro is clinically appropriate for you.